REVIEW ARTICLE Current management of gout: practical messages from 2016 EULAR guidelines 267 where these differ significantly from the earli er guidelines and other recent national and in ternational recommendations for the manage ment of gout.
Comment Lifestyle interventions and dietary modification are frequently a matter of consider able concern to patients with gout. Although their effects on SU levels are small, 17 there is consen sus among physicians with expertise and expe rience in gout that lifestyle education and coun selling should be one of the overarching princi ples of management.
There is some evidence that weight reduction following dietary intervention or bariatric sur gery in obese individuals is effective in reduc ing SU levels, 18,19 and regular physical activity has been shown to be associated with some re duction of the excess mortality in patients with chronic hyperuricemia. 20 A systematic review of observational studies has confirmed excessive consumption of meat, seafood, alcoholic drinks (especially beer and spir its), sugar sweetened soft drinks, and fructose containing foods as significant modifiable risk factors for incident gout, 21 and binge drinking as being associated with an increased risk of recur rent gout attacks, regardless of the type of alcohol consumed. 22 Consumption of low fat dairy prod ucts, folate, coffee, and diets high in dietary fi ber are associated with a reduced risk of incident gout and can reduce recurrent gout flares. 23 Fruit and vitamin C supplements (500 mg/d) have only a very modest uricosuric effect, 24 but consump tion of cherries or cherry extract can diminish the frequency of acute attacks.
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Principle C Every person with gout should be sys tematically screened for associated comorbidities and cardiovascular risk factors, including renal impairment, coronary heart disease, heart failure, stroke, peripheral artery disease, obesity, hyper lipidemia, hypertension, diabetes, and smoking, which should be addressed as an integral part of the management of gout.
Comment Screening for comorbidities is advis able because of their frequency, 2,3 their impor tance for patients' overall health, and the thera peutic implications of their presence for the phar macotherapy of gout. Detection of chronic kid ney disease (CKD) is particularly required, and the EULAR guideline recommends measurement of the estimated glomerular filtration rate (eGFR) at the time of diagnosis followed by subsequent monitoring in parallel with measurements of SU levels. The importance of controlling gout and hyperuricemia, as well as treating comorbidities directly, is highlighted by studies demonstrating that allopurinol slows the progression of renal dis ease in patients with CKD and hyperuricemia 26 and that gout is an independent risk factor for mortality of CKD and coronary heart disease. of safe, effective, and potentially "curative" ther apy for more than 50 years. 4 Research studies and audits showed that less than 50% of patients with gout seen in general practice received urate lowering therapy (ULT) 2, 9 and that many patients with gout being treated with ULT in both primary 3 and secondary care 10 did not achieve reductions of serum urate (SU) to the most conservative target level of 360 µmol/l recommended in EULAR and most other guide lines. 5 Attention had been drawn to a range of pa tient and provider barriers to effective care, 11 and a preliminary proof of principle study had dem onstrated that these barriers could be overcome, and outcomes improved, with better provision of information and a package of care based on guideline recommendations. 12 6 In their 2013 revision of criteria for inclusion of clinical practice guidelines in the United States (US) National Guideline Clearinghouse, the Agen cy for Healthcare Research and Quality (AHRQ) stipulated that guidelines must have been de veloped, reviewed, or revised within the last 5 years. 13 EULAR overarching principles The updated rec ommendations emphasize 3 overarching prin ciples that are central to the effective manage ment of gout.
Principle A Every person with gout should be ful ly informed about the pathophysiology of the dis ease, the existence of effective treatments, asso ciated comorbidities, and the principles of man aging acute attacks and eliminating urate crys tals through lifelong lowering of the SU level be low a target level.
Comment Patient and physician education is es sential if patient and provider barriers 11 to effec tive care are to be overcome. A number of stud ies have shown that inadequate understanding of the causes and consequences of gout, together with distorted, stereotypical, and generally neg ative views about gout and its treatment, are as sociated with lower adherence to ULT and sub optimal disease control.
14-16 A proof of concept observational study has demonstrated that with full patient education, treatment to target with ULT, and nurse follow up, 98 of 106 patients achieved the therapeutic target, adherence to treatment at 1 year was excellent, and there were improvements in pain and other patient centered outcomes. 12
Principle B Every person with gout should re ceive advice regarding lifestyle: weight loss if ap propriate and avoidance of alcohol (especially beer and spirits) and sugar sweetened drinks, heavy meals and excessive intake of meat and seafood. Low fat dairy products should be encouraged. Regular exercise should be advised.
The efficacy of colchicine, 29 NSAIDs, 30 and oral corticosteroids 31,32 is supported by a rela tively small number of moderate quality random ized controlled trials (RCTs). In a US study, self administration of colchicine (1.2 mg followed af ter 1 hour by a dose of 0.6 mg) was shown to be as effective as high dose colchicine, when taken within 12 hours of symptom onset, with no more side effects than placebo. 33 As colchicine is avail able in Europe as 0.5 mg rather than 0.6 mg tab lets, the EULAR recommendation is for immedi ate administration of 1 mg followed by 0.5 mg af ter an hour without further colchicine on the first day, and this can be followed by 0.5 mg once or First line options are oral colchicine, a nonste roidal anti inflammatory drug (NSAID) with gas troprotection, or an oral or intraarticular cortico steroid. Without evidence that any of these are consistently more effective, 28 the choice should be determined by the presence or absence of con traindications and individual patient preference. Fully informed patients for whom an oral agent is appropriate should have a supply of the preferred agent to hand and should be advised to start treat ment of an acute attack as early as possible. Acute flares of gout should be treated as early as possible. Fully informed patients should be educated to self -medicate at the first warning symptoms. The choice of drug or drugs should be based on the presence of contraindications, the patient's previous experience with treatments, time of initiation after flare onset, and the number and type of joint(s) involved. 
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In patients with frequent flares and contraindications to colchicine, NSAIDs and corticosteroid (oral and injectable), IL -1 blockers should be considered for treating flares. Current infection is a contraindication to the use of IL -1 blockers. ULT should be adjusted to achieve the uricemia target following an IL -1 blocker treatment for flare.
4
Prophylaxis against flares should be fully explained and discussed with the patient. Prophylaxis is recommended during the first 6 months of ULT. Recommended prophylactic treatment is colchicine, 0.5-1 mg/d, a dose that should be reduced in patients with renal impairment. In cases of renal impairment or statin treatment, patients and physicians should be aware of potential neurotoxicity and muscular toxicity with prophylactic colchicine. Coprescription of colchicine with strong P -glycoprotein and CYP3A4 inhibitors should be avoided. If colchicine is not tolerated or is contraindicated, prophylaxis with NSAIDs at low doses, if not contraindicated, should be considered.
5
ULT should be considered and discussed with every patient with a definite diagnosis of gout from the first presentation. ULT is indicated in all patients with recurrent flares, tophi, urate arthropathy, or renal stones. Initiation of ULT is recommended close to the time of the first diagnosis in patients presenting at a young age (<40 years) or with a very high SU level (>8.0 mg/dl; 480 µmol/l) and in those with comorbidities (eg, renal impairment, hypertension, ischemic heart disease, or heart failure). Patients with gout should receive full information and be fully involved in decision making concerning the use of ULT.
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For patients on ULT, SU level should be monitored and maintained to <6 mg/dl (360 µmol/l). A lower SU target (<5 mg/dl; 300 µmol/l) to facilitate faster dissolution of crystals is recommended for patients with severe gout (tophi, chronic arthropathy, frequent attacks) until total crystal dissolution and resolution of gout. SU level <3 mg/dl is not recommended in the long term.
7
All ULTs should be started at a low dose and then titrated upwards until the SU target is reached. SU <6 mg/dl (360 µmol/l) should be maintained lifelong.
8
In patients with normal kidney function, allopurinol is recommended for first -line ULT, starting at a low dose (100 mg/d) and increasing by 100 -mg increments every 2-4 weeks if required, to reach the uricemia target.
If the SU target cannot be reached by an appropriate dose of allopurinol, allopurinol should be switched to febuxostat or a uricosuric or combined with a uricosuric. Febuxostat or a uricosuric is also indicated if allopurinol cannot be tolerated.
9
In patients with renal impairment, the maximum allopurinol dose should be adjusted to creatinine clearance. If the SU target cannot be achieved at this dose, the patient should be switched to febuxostat or given benzbromarone with or without allopurinol, except in patients with estimated glomerular filtration rate <30 ml/min/1.73 m 2 .
cyclosporine, cimetidine, clarithromycin, eryth romycin, ketoconazole, and verapamil ), and should be used with caution and at low doses in patients taking drugs which are potent inhibitors of P glyco protein or cytochrome P450 3A4 (CYP3A4) (eg, Treat as early as possible (1) Resolution of flare Avoid colchicine (2) Colchicine (2) (1 mg followed 1 hour later by 0.5 mg) NSAID (2) (classic or coxibs + PPI if appropriate) Prednisolone (2) (30-35 mg/d for 3-5 days)
Intraarticular injections of corticosteroid (2) Combination therapy (2) (for instance colchicine + NSAID or corticosteroids)
Consider IL-1 blockers (3) Educate to self-medicate (1) Consider initiation of ULT (5) (together with flare prophylaxis) Avoid colchicine and NSAIDs (2) Education about the disease (A) Individualized lifestyle advice (B) Screening for comorbidities and current medications (C,2) 
EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF FLARES IN PATIENTS WITH GOUT
Severe renal failure Therapeutic options (1) Abbreviations: PPI, proton pump inhibitor; others, see TABLE 1 250 mg twice daily) for up to 6 months is support ed by evidence from RCTs and observational stud ies. 39 Patients and physicians need to be aware, however, that there is a risk of neurotoxicity and myopathy with colchicine prophylaxis in patients with renal impairment and in patients receiving statins, so renal function should be assessed be fore prescribing colchicine or NSAIDs. It is rec ommended that colchicine prophylaxis should be avoided altogether in patients needing treatment with strong P glycoprotein or CYP3A4 inhibitors such as cyclosporine, clarithromycin, and eryth romycin. As the propensity for flares is related to the speed and extent of SU reduction, prophylax is is particularly required in patients starting ULT with febuxostat (80 mg/d) as this lowers the SU level to a greater degree than the starting dose of allopurinol (100 mg/d). By contrast, slow up ward titration of allopurinol from this low start ing dose was accomplished without a significant increase in flares in patients in the Nottingham proof of concept study that chose not to take any drug prophylaxis. 12 The efficacy and safety of using corticosteroids for flare prophylaxis have not been investigated in RCTs or observational studies. Although there is some evidence for prophylactic efficacy of IL 1 inhibitors, 40 none of them are approved for this indication by the EMA, and it seems likely that the cost of these biologics will always preclude their use for flare prophylaxis.
Management of hyperuricemia
The EULAR rec ommendations for managing hyperuricemia in patients with gout (4-11 in TABLE 1) are summa rized in FIGURE 2.
Urate -lowering therapy Treating gout patients with ULT to lower the SU level below its saturation threshold to prevent crystal formation and pro mote crystal dissolution has been a principle of management for more than 50 years. 8 In the last decade, data from trials and observational studies have shown that prolonged ULT can reduce gout flares 41, 42 and tophi [41] [42] [43] and improve the quality of life of patients with chronic gouty arthritis.
1,44-46
Treatment of patients with gout and urolithiasis with ULT is supported by observational studies, 47 while the recommendation to consider ULT in pa tients taking diuretic drugs is supported by co hort and case control studies which demonstrat ed higher risks of gouty arthritis in users com pared with nonusers of diuretics.
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The more recent recommendation to consider treatment with ULT in all patients with gout is based on expert opinion, emerging evidence from imaging studies suggesting that gout is a chron ic crystal deposition disease even at the time of the first attack, 49 and studies indicating cardiovas cular 50,51 and renal 52 benefits from treatment with xanthine oxidase inhibitors (XOIs). Neverthe less, the EULAR guideline acknowledges a need for further RCTs specifically designed to exam ine the effects of XOIs on cardiovascular and renal 
In patients with very severe, or polyarticular flares, treatment with combinations of colchicine with NSAIDs or corticosteroids should be consid ered. In patients with frequent flares and contra indications to colchicine, NSAIDs, and cortico steroids, interleukin (IL)1 blockers should also be considered.
A single subcutaneous (SC) dose of 150 mg of the anti IL 1β monoclonal antibody canakinum ab was more effective than triamcinolone (40 mg SC) in an RCT in such patients.
36 Canakinum ab is licensed for use in Europe by the Europe an Medicines Agency (EMA) for patients with gout flares and contraindications to colchicine, NSAIDs, and corticosteroids, but it has not re ceived Food and Drug Administration approval in the US because of uncertainty about its risk to benefit ratio. Although not licensed or sup ported by RCTs for the treatment of gout, ob servational studies have suggested that the IL 1β receptor antagonist anakinra (100 mg SC on 3 consecutive days) can also be effective in pa tients with severe gout flares.
37 Current infec tion is an important contraindication to the use of IL 1 blockers, and ULT should be adjusted to achieve the SU target following treatment of acute gout with an IL 1 blocker. The ongoing uncertain ty concerning the overall benefits and harms of IL 1 inhibitors for treating patients with gout are reflected in a Cochrane review. 38 Flare prophylaxis Initiation of ULT is often fol lowed by an increase in the frequency of acute gout attacks. As this can be an important con tributor to poor treatment adherence, the risk of flares and options for prophylaxis should be fully explained and discussed before ULT is start ed. Recommended prophylaxis with colchicine (0.5-1 mg/d) or a low dose NSAID (naproxen, treatment with ULT drew support from a 1995 health economic study in a Canadian health care setting, which showed that only 62% of patients with nontophaceous gout had a second attack outcomes as there are also contradictory obser vational data that did not show cardiovascular benefit or improvement in renal function with XOIs. 53 
,54 Previous recommendations to delay
Determine the SU target (6) Start prophylactic treatment (4) Education about the disease (A) Individualized lifestyle advice (B) Screening for comorbidities (C) Start allopurinol 100 mg/d (8) Adapt the dosage to renal function (9) Slow titration (7) up to the maximum allowed dosage
EULAR RECOMMENDATIONS FOR THE MNAGEMENT OF HYPERCURICEMIA IN PATIENTS WITH GOUT
Initiate ULT (5) Start pegloticase (10) (8, 9) or uricosuric (8, 9) Start febuxostat or uricosuric or History of allergy to allopurinol Achieve target (6) Achieve target (6) Achieve target (6) No
No No Yes
Yes Yes Continue (7) Continue (7) Consider a combined therapy (XOI and uricosuric) (10) SUA target not achieved Abbreviations: XOI, xanthine oxidase inhibitor; others, see TABLE 1 allopurinol should be switched to febuxostat or a uricosuric, or combined with a uricosuric. Although well tolerated by the majority of pa tients, allopurinol is rarely (0.7/1000 patient years of exposure) 69 associated with potential ly life threatening SCARs including toxic epi dermal necrolysis, Stevens-Johnson syndrome, and hypersensitivity drug reactions with rash, eosinophilia, and systemic symptoms; and it is the drug most frequently associated with toxic epidermal necrolysis and Stevens-Johnson syn drome in Europe. 70 Because the risk and the se verity of SCARs are increased in patients with im paired renal function, 71,72 the EULAR guideline recommends that in patients with renal insuffi ciency, the maximum dose of allopurinol should be adjusted to the creatinine clearance (CrCl). 73 If the SU target cannot be achieved at this dose, the patient should be switched to febuxostat or given benzbromarone with or without allopuri nol, except in patients with eGFR of less than 30 ml/min/1.73 m 2 .
Unfortunately, observational studies have shown that allopurinol dose adjustment accord ing to CrCl seldom results in adequate reduction of SU levels in patients with gout and renal insuf ficiency, 74 and a case controlled study showed no evidence of a reduction in frequency of allopuri nol hypersensitivity in patients dosed according to CrCl. 75 Subsequent studies suggested that low ering the starting dose of allopurinol appropriate to the level of renal function reduces the risk of allopurinol hypersensitivity, 66 and that a gradu al increase in the dose above the dose based on CrCl resulted in a reduction of SU to target lev els in most patients without any increase in tox icity. 76 Although this strategy for using allopu rinol in patients with renal insufficiency is en dorsed in the American College of Rheumatol ogy (ACR) recommendations, 65 the EULAR task force recommended adhering to the more conser vative approach of adjusting the maximum dose of allopurinol to the CrCl 73 because of the poten tial severity of SCARs, the availability of febuxo stat as a therapeutic alternative, and the limited number of patients in the studies of Stamp et al 66 and Seth et al.
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Febuxostat is a potent, nonpurine selective XOI, which is effective 45 and cost effective as second line ULT. 68, 77 As it is metabolized in the liver, it can be used for patients whose renal insufficiency precludes allopurinol dose escalation. 78 It should be started with a dose of 80 mg/d and the dose should be increased, if necessary, to 120 mg/d after 4 weeks to reach the therapeutic target for SU levels. At these doses, it has greater urate lowering efficacy than allopurinol in its widely used fixed dose of 300 mg/d but the risk of gout flares following initiation of treatment is great er. 45 It is otherwise generally well tolerated, and despite rare case reports of SCARs in patients re ceiving febuxostat, a previous history of a mild hypersensitivity rash with allopurinol should not 55 Additional local and more contemporary studies of this kind could help physicians and patients with gout de cide when best to commence ULT. The recommen dation to start ULT early in younger patients and in those with high SU (>8 mg/dl or 480 µmol/l) is supported by studies demonstrating younger age as a marker of gout severity 56 and increased fre quency of flares with higher SU level. 57 However, the decision as to when to start ULT in any indi vidual should also be influenced by the patient's comorbidities, potential contraindications, drug intolerance or drug interactions, and of course must be ultimately determined by the patient fol lowing full explanation and discussion of poten tial benefits and harms. Treatment with ULTs to lower and maintain the SU level below its satu ration threshold in all patients with gout using a treat to target strategy is a key guideline rec ommendation. All ULTs should be started at a low dose and then titrated upwards until the SU tar get of 6 mg/dl (360 µmol/l) or lower is reached. A lower SU target, of 5 mg/dl (300 µmol/l) or low er, is recommended for patients with frequent flares, chronic arthritis, or clinically evident tophi, in whom the crystal burden is greater, as there is evidence that this will facilitate more rapid crys tal dissolution. 58 Subsequent ULT dose reduction to the less stringent target of SU of 360 µmol/l or lower is recommended to avoid further crystal de position when tophi have resolved and the patient is free from flares. 59 Current advice is to avoid pro longed reduction of SU below 300 µmol/l because of a possible association between low levels and both incidence 60 and progression 61 of Parkinson disease and other neurodegenerative disorders.
The updated EULAR guideline makes no specif ic recommendation with regard to whether ULT should be initiated during a gout flare despite some evidence that doing so does not increase the severity, or prolong the duration, of acute gout attacks.
62,63 There is, however, widespread consensus that ULT should not be discontinued in the event of a gout flare. 64, 65 Xanthine oxidase inhibitors Allopurinol is the rec ommended first line ULT. It should be started at a low dose (100 mg/d) to reduce the risk of precipi tating gout flares 12 and rare serious cutaneous ad verse reactions (SCARs).
66 The dose should then be increased in 100 mg increments every 2 to 4 weeks until the SU target or maximum dose has been reached. This dose escalation strategy is safe, effective, 12,67 and cost effective. 68 The median dose of allopurinol required to achieve the thera peutic SU target of 360 µmol/l or lower in more than 90% of patients was only 400 mg/d, 12 but in general practice less than 50% of patients at tain this target with the most widely prescribed dose of 300 mg/d. 3, 9 If the SU target cannot be reached with an appropriate dose of allopurinol, urate lowering efficacy when administered to gout patients receiving ULT with allopurinol or benzbromarone. 91 Uricase Pegloticase is a polyethylene glycol mod ified uricase produced in a genetically modified strain of Escherichia coli. It has EMA marketing authorization and is recommended by the EULAR for treating patients with crystal proven, severe, debilitating chronic tophaceous gout and poor quality of life, in whom the SU target cannot be reached with any other available ULT, or combi nation of drugs, at the maximum dosage. Two RCTs have shown it to be effective in such pa tients with improvements in pain, function, and quality of life as well as reduction in flares, tophi, and SU levels, 42 but despite heavy pegylation it is immunogenic. Pegloticase should be given by intravenous infusion (8 mg in 250 ml normal sa line over 2 hours) every 2 weeks by physicians with experience and facilities for dealing with infusion reactions. Patients should be pretreat ed with antihistamines and steroids to reduce the risk of infusion reactions, in addition to low dose colchicine or NSAIDs for flare prophylaxis. SU levels should be measured before each infu sion, and treatment discontinued if, after initial decrease, the SU level exceeds 360 µmol/l as tran sient responders (about 50%) appear to be at in creased risk for infusion reactions and anaphy laxis. Pegloticase is contraindicated in patients with glucose 6phosphate dehydrogenase defi ciency because of the risk of hemolysis, and ex tra caution is required in patients with conges tive heart failure.
Alternative recommendations in other contemporary guidelines Most of the 2016 EULAR rec ommendations for the management of gout 6 are very similar to recommendations in other cur rent evidence based, expert consensus guide lines from international rheumatology societ ies. 65,92,93 A few differences in the 2012 ACR guide lines, 65,92 which are discussed elsewhere in greater detail, 94 include: 1) the recommendation to con sider commencement of ULT during the course of a gout flare; 2) the use of low dose corticoste roids (prednisolone <10 mg/d) for flare prophy laxis if colchicine and NSAIDs are contraindicat ed; 3) the use of febuxostat as well as allopurinol for first line ULT; 4) careful uptitration of allopu rinol in patients with impairment of renal func tion; and 5) screening Koreans with CKD stage 3 or worse and all patients of Han Chinese and Thai descent for HLA B*5801 before considering ULT with allopurinol, 65 because of a greatly increased risk of allopurinol induced SCARs in subjects car rying this variant allele and a high allele frequen cy (6%-12%) in these ethnic groups. 95 Screening for HLA B*5801 is not currently recommended in Europe where the risk of developing allopurinol induced SCARs in HLA B*5801 positive individ uals is lower 96, 97 and the allele frequency in Cau casians is lower (1%-2%).
be a contraindication to the use of febuxostat as cross reactivity does not appear to be a problem. 79 Uricosurics The uricosuric drugs probenecid (1-2 g/d) and sulfinpyrazone (200-800 mg/d) can be used as alternative ULTs 80 in patients with normal, or only mildly impaired, renal function, who are intolerant of allopurinol, or whose SU is not adequately controlled by an XOI. Benzbro marone (50-200 mg/d) is more potent and can be used in patients with moderate renal impair ment (eGFR >30 ml/min/1.73 m 2 ). 81 All uricosu rics are contraindicated or need to be used with great caution in patients with urolithiasis or se vere renal impairment. In RCTs in patients who did not achieve target SU levels or tolerate allopu rinol at a dose of 300 mg/d, benzbromarone at a dose of 200 mg/d was more effective and better tolerated than 2 g/d of probenecid, 82 and benz bromarone at a dose of 200 mg/d was highly ef fective and approximately equipotent with allo purinol at a dose of 600 mg/d in lowering SU to target levels. 83 Although generally well tolerated, the use of benzbromarone has been restricted fol lowing rare reports of severe hepatotoxicity. Pa tients treated with benzbromarone should have liver function tests monitored but the risk of seri ous hepatotoxicity in patients receiving the ben zbromarone in Europe is only approximately 1 in 17 000 patients. 84 The EULAR recommendation to consider addition of a uricosuric when treat ment with allopurinol alone has failed to lower the SU to target levels is based on observational studies of an effective combination of allopuri nol with benzbromarone 85 or probenecid. 86 Since the completion of the 2016 EULAR recommen dations, the EMA has granted marketing autho rization for the novel uricosuric lesinurad for combination therapy with an XOI for the treat ment of hyperuricemia associated with gout in patients who have not achieved SU target levels with an XOI alone. In phase III placebo controlled RCTs, the addition of lesinurad (200 mg/d) to pa tients receiving allopurinol (300 mg/d) was safe and effective in increasing the number of patients achieving target SU reduction by 55%, 87 but high er doses and monotherapy are not recommended as they can cause renal impairment.
When gout occurs in a patient receiving a loop or thiazide diuretic for control of hypertension, the possibility of substituting the diuretic with losartan or a calcium channel blocker should be considered, provided that the blood pressure re mains controlled. Calcium channel blockers and losartan are mildly uricosuric, unlike β blockers and other angiotensin II receptor antagonists, and both have been associated with a significant ly reduced risk of incident gout in a community based case control study. 88 The lipid lowering agent fenofibrate 89 and statins 90 are also mod estly uricosuric and should be considered when prescribing treatment for hyperlipidemia in pa tients with gout. Losartan (50 mg/d) and feno fibrate (300 mg/d) both had some additional Conclusions Surprisingly, the recommendation to eliminate urate crystals through lifelong low ering of SU below a target level, which is one of the overarching EULAR principles, and a key rec ommendation in all guidelines for the manage ment of gout from international rheumatology societies, 6, 65, 92, 93 has recently been challenged in a clinical practice guideline from the American College of Physicians (ACP). 98 Based on a system atic evidence review sponsored by the AHRQ and conducted by the RAND Corporation's South ern California Evidence based Practice Center, the ACP concluded that it was inappropriate to recommend a treat to target strategy as this was not supported by RCT evidence of clinical benefit, such as reduction in the frequency of gout flares, but mainly by retrospective studies and studies that used SU as the primary outcome measure. The ACP guideline recommends "treatment to avoid symptoms" without monitoring SU levels. There is, however, no evidence to support the ef ficacy or safety of such an approach, which is sim ilar to the current standard of care for patients with gout in general practice, 2,3,9 and which has notably failed to prevent the rising prevalence of gout.
7 By contrast, a nurse led treatment to target approach following the EULAR recommen dations resulted in a reduction of SU levels to tar get in more than 90% of patients and improve ments in patient centered outcomes and quality of life, when compared with general practitioner led usual care, in a 2 year community based com parative effectiveness RCT in over 500 patients with gout in the United Kingdom. 99 
